Notes![what is notes.io? What is notes.io?](/theme/images/whatisnotesio.png)
![]() ![]() Notes - notes.io |
In all treatment sites of our radiotherapy network, in vivo dosimetry (PerFRACTION™) was fully implemented in February 2018. We hypothesized that additional help with bladder and rectum preparation by home nursing would improve patients' preparation and investigated if this could be assessed using in vivo dosimetry (IVD).
A retrospective study was conducted with a test group who received additional help with bladder and rectum preparation by home nurses and a control group who only received information on bladder and rectum preparation according to the standard protocol. Patients were treated with a 6 MV Volumetric Modulated Arc Therapy (VMAT) technique. Electronic portal imaging device (EPID)-based integrated transit dose images were acquired on the first 3 days of treatment and weekly thereafter or more if failed fractions (FF) occurred. Results were analyzed using a global gamma analysis with a threshold of 20%, tolerance of 5% (dose difference) and 5 mm (distance to agreement), and a passing level of 95%.
Data of 462 prostate patients was analyzed 39 and 423 in a test and control group respectively with a comparable number of measurements (on average 8.0 (σ = 4.8) and 7.1 (σ = 4.5) respectively per treatment course). Of the FF, 39% and 31% were related to variations in bladder and rectum filling for the test and control group respectively. Subgroups were created based on the number of FF, no statistically significant differences were observed.
Two dimensional EPID-based IVD successfully detected deviations due to variations in bladder and rectum filling, however it could not confirm the hypothesis.
Two dimensional EPID-based IVD successfully detected deviations due to variations in bladder and rectum filling, however it could not confirm the hypothesis.
The relation between radiotherapy (RT) dose to the brain and morphological changes in healthy tissue has seen recent increased interest. There already is evidence for changes in the cerebral cortex and white matter, as well as selected subcortical grey matter (GM) structures. We studied this relation in all deep GM structures, to help understand the aetiology of post-RT neurocognitive symptoms.
We selected 31 patients treated with RT for grade II-IV glioma. Pre-RT and 1year post-RT 3D T1-weighted MRIs were automatically segmented, and the changes in volume of the following structures were assessed amygdala, nucleus accumbens, caudate nucleus, hippocampus, globus pallidus, putamen, and thalamus. The volumetric changes were related to the mean RT dose received by each structure. Hippocampal volumes were entered into a population-based nomogram to estimate hippocampal age.
A significant relation between RT dose and volume loss was seen in all examined structures, except the caudate nucleus. The volume loss neurocognitive functioning in glioma patients, future studies are needed that directly correlate volumetrics to clinical outcomes.
For muscle-invasive bladder cancer, bladder preserving chemoradiotherapy (BPCRT) has shown to be a viable alternative for patients with urothelial carcinoma (UCa). Traditionally bladder cancer with variant histology UCa or other tumors types involving the bladder have worse outcomes and BPCRT has been contraindicated. Rapamycin However, there is limited high level evidence for this recommendation.
The National Cancer Database (NCDB) was queried for all patients with Bladder cancer treated from 2004 to 2015 restricted to clinical stage T2-4, N0, M0 who had variants of UCa or other tumors types involving the bladder (e.g. adenocarcinoma and squamous cell carcinoma). Only patients treated with definitive intent with either radical cystectomy or BPCRT after maximal transurethral tumor resection were analyzed. Propensity-score matching was used.
356 patients had BPCRT and 2093 patients had definitive surgery for muscle-invasive bladder cancer limited to variants of UCa and other tumors types involving the bladder. On rvival compared to cystectomy in patients with selected variant histology but with worse OS for adenocarcinoma or squamous cell carcinoma specifically. As our study has inherent limitations, these hypotheses require validation in a prospective setting and/or with a larger sample size.
Patients who receive carbon-ion radiotherapy (C-ion RT) for primary pancreatic cancer may experience locoregional recurrence; however, the treatment options for such patients are limited. We aimed to investigate the feasibility and efficacy of carbon-ion re-irradiation for patients with pancreatic cancer who experienced recurrence after initial C-ion RT.
Twenty-one patients with recurrent pancreatic cancer who underwent repeat C-ion RT between December 2010 and November 2016 at our institute were retrospectively evaluated. The sites of post-initial C-ion RT failure were in-field central in 16 patients (76.2%) and marginal in 5 (23.8%). The median doses of initial and repeat C-ion RT were both 52.8Gy (relative biological effectiveness [RBE]). Thirteen patients (61.9%) received concurrent chemotherapy with re-irradiation, while 11 (52.4%) received adjuvant chemotherapy.
The median follow-up period after re-irradiation was 11months. The 1-year local control, progression-free survival, and overall survival ter initial C-ion RT.Heat-Not-Burn (HNB) products, generating vapor without combusting tobacco leaves, have been developed with the expectation that the number and quantity of chemicals in the vapor of these products would be reduced compared with the smoke from conventional combustible cigarettes. However, whether the lower chemical levels correlate with lower toxicity remains to be determined. Here we examined differences in the biological effects of conventional cigarette smoke (CS) and two HNB products, Ploom TECH and Ploom TECH+, using the cultured cancer cell line A549 and the normal bronchial epithelium cell line BEAS-2B. The conventional CS 3R4F extract (0.5%) markedly decreased cell proliferation of both A549 and BEAS-2B cells; however, 0.5% extracts of these commercially available HNB products did not affect cell growth. To determine the cause of decreased cell proliferation, a TUNEL assay was performed, and the results indicated that apoptosis had occurred in both A549 and BEAS-2B cells at 24 h after exposure to 3R4F. To further explore the effect of CS on epigenetics, we performed western blotting to detect histone H2A phosphorylation, which is known to affect transcriptional regulation.
Homepage: https://www.selleckchem.com/products/Rapamycin.html
![]() |
Notes is a web-based application for online taking notes. You can take your notes and share with others people. If you like taking long notes, notes.io is designed for you. To date, over 8,000,000,000+ notes created and continuing...
With notes.io;
- * You can take a note from anywhere and any device with internet connection.
- * You can share the notes in social platforms (YouTube, Facebook, Twitter, instagram etc.).
- * You can quickly share your contents without website, blog and e-mail.
- * You don't need to create any Account to share a note. As you wish you can use quick, easy and best shortened notes with sms, websites, e-mail, or messaging services (WhatsApp, iMessage, Telegram, Signal).
- * Notes.io has fabulous infrastructure design for a short link and allows you to share the note as an easy and understandable link.
Fast: Notes.io is built for speed and performance. You can take a notes quickly and browse your archive.
Easy: Notes.io doesn’t require installation. Just write and share note!
Short: Notes.io’s url just 8 character. You’ll get shorten link of your note when you want to share. (Ex: notes.io/q )
Free: Notes.io works for 14 years and has been free since the day it was started.
You immediately create your first note and start sharing with the ones you wish. If you want to contact us, you can use the following communication channels;
Email: [email protected]
Twitter: http://twitter.com/notesio
Instagram: http://instagram.com/notes.io
Facebook: http://facebook.com/notesio
Regards;
Notes.io Team